Ganglioside therapy and guillain-barré syndrome: A historical cohort study in Ferrara, Italy, fails to demonstrate an association

Enrico Granieri; Ilaria Caselta; Vittorio Govoni; Maria R. Tola; Ezio Paolino; Walter A. Rocca

doi:10.1159/000110265

Ganglioside therapy and guillain-barré syndrome: A historical cohort study in Ferrara, Italy, fails to demonstrate an association

Enrico Granieri, Ilaria Caselta, Vittorio Govoni, Maria R. Tola, Ezio Paolino, Walter A. Rocca

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

We investigated an alleged association between ganglioside therapy and the risk of developing the Guillain-Barre syndrome (GBS) in a historical cohort study. Using official medical records of the Local Health Unit No. 31 of Ferrara Province, northern Italy, we linked data on sales of gangliosides with information regarding hospital admissions and discharge diagnoses between January 1, 1988, and May 31, 1990. The number of incidence cases of GBS observed within 30 days of gangliosides administration in a cohort of 13,373 treated subjects (0.0 cases) was not significantly different from that expected in the general population (0.014). Our study suggests that patients receiving gangliosides are not at increased risk of developing GBS. However, because of sample size limitations, these findings should be confirmed in a larger cohort study.

Original language	English (US)
Pages (from-to)	161-169
Number of pages	9
Journal	Neuroepidemiology
Volume	10
Issue number	4
DOIs	https://doi.org/10.1159/000110265
State	Published - 1991

Keywords

Cohort study
Epidemiology
Gangliosides
Guillain-Barré syndrome

ASJC Scopus subject areas

Epidemiology
Clinical Neurology

Access to Document

10.1159/000110265

Cite this

@article{4146d4cc82234a7896fd360fc012baee,

title = "Ganglioside therapy and guillain-barr{\'e} syndrome: A historical cohort study in Ferrara, Italy, fails to demonstrate an association",

abstract = "We investigated an alleged association between ganglioside therapy and the risk of developing the Guillain-Barre syndrome (GBS) in a historical cohort study. Using official medical records of the Local Health Unit No. 31 of Ferrara Province, northern Italy, we linked data on sales of gangliosides with information regarding hospital admissions and discharge diagnoses between January 1, 1988, and May 31, 1990. The number of incidence cases of GBS observed within 30 days of gangliosides administration in a cohort of 13,373 treated subjects (0.0 cases) was not significantly different from that expected in the general population (0.014). Our study suggests that patients receiving gangliosides are not at increased risk of developing GBS. However, because of sample size limitations, these findings should be confirmed in a larger cohort study.",

keywords = "Cohort study, Epidemiology, Gangliosides, Guillain-Barr{\'e} syndrome",

author = "Enrico Granieri and Ilaria Caselta and Vittorio Govoni and Tola, {Maria R.} and Ezio Paolino and Rocca, {Walter A.}",

year = "1991",

doi = "10.1159/000110265",

language = "English (US)",

volume = "10",

pages = "161--169",

journal = "Neuroepidemiology",

issn = "0251-5350",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Ganglioside therapy and guillain-barré syndrome

T2 - A historical cohort study in Ferrara, Italy, fails to demonstrate an association

AU - Granieri, Enrico

AU - Caselta, Ilaria

AU - Govoni, Vittorio

AU - Tola, Maria R.

AU - Paolino, Ezio

AU - Rocca, Walter A.

PY - 1991

Y1 - 1991

N2 - We investigated an alleged association between ganglioside therapy and the risk of developing the Guillain-Barre syndrome (GBS) in a historical cohort study. Using official medical records of the Local Health Unit No. 31 of Ferrara Province, northern Italy, we linked data on sales of gangliosides with information regarding hospital admissions and discharge diagnoses between January 1, 1988, and May 31, 1990. The number of incidence cases of GBS observed within 30 days of gangliosides administration in a cohort of 13,373 treated subjects (0.0 cases) was not significantly different from that expected in the general population (0.014). Our study suggests that patients receiving gangliosides are not at increased risk of developing GBS. However, because of sample size limitations, these findings should be confirmed in a larger cohort study.

AB - We investigated an alleged association between ganglioside therapy and the risk of developing the Guillain-Barre syndrome (GBS) in a historical cohort study. Using official medical records of the Local Health Unit No. 31 of Ferrara Province, northern Italy, we linked data on sales of gangliosides with information regarding hospital admissions and discharge diagnoses between January 1, 1988, and May 31, 1990. The number of incidence cases of GBS observed within 30 days of gangliosides administration in a cohort of 13,373 treated subjects (0.0 cases) was not significantly different from that expected in the general population (0.014). Our study suggests that patients receiving gangliosides are not at increased risk of developing GBS. However, because of sample size limitations, these findings should be confirmed in a larger cohort study.

KW - Cohort study

KW - Epidemiology

KW - Gangliosides

KW - Guillain-Barré syndrome

UR - http://www.scopus.com/inward/record.url?scp=0025744518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025744518&partnerID=8YFLogxK

U2 - 10.1159/000110265

DO - 10.1159/000110265

M3 - Article

C2 - 1745325

AN - SCOPUS:0025744518

SN - 0251-5350

VL - 10

SP - 161

EP - 169

JO - Neuroepidemiology

JF - Neuroepidemiology

IS - 4

ER -

Ganglioside therapy and guillain-barré syndrome: A historical cohort study in Ferrara, Italy, fails to demonstrate an association

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this